Bloodstream infections in patients given treatment with intravenous prostanoids

Infection Control and Hospital Epidemiology

Volumn 29, Issue 4, 2008, Pages 342-349

  Kallen, Alexander J ^a,b   Lederman, Edith ^b   Balaji, Alexandra ^b   Trevino, Ingrid ^b   Petersen, Emily E ^b   Shoulson, Rivka ^b   Saiman, Lisa ^c,d   Horn, Evelyn M ^d   Gomberg Maitland, Mardi ^e   Barst, Robyn J ^c   Srinivasan, Arjun ^a  

^a NATIONAL CENTER FOR PREPAREDNESS DETECTION AND CONTROL OF INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c New York Presbyterian Hospital ^*  (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; PROSTANOID; UNIPROST;

ADULT; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; GRAM NEGATIVE INFECTION; HEALTH SURVEY; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PUBLIC HEALTH SERVICE; SEPSIS;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; BACTEREMIA; CATHETERS, INDWELLING; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COHORT STUDIES; CROSS INFECTION; EPOPROSTENOL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOME INFUSION THERAPY; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDINS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 40949101444     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/529552     Document Type: Article

References (23)

1. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106:1477-1482.
2. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-302.
3. Lang I, Gomez-Sanchez M, Kneussel M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006; 129:1636-1643.
4. Gomberg-Maitland M, Tapson V, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172:1586-1589.
5. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40:780-788.
6. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12 week trial. Chest 2006; 129:683-688.
7. Roberts TG Jr, Chabner BA. Beyond fast track for drug approvals. N Engl J Med 2004; 351:501-505.
8. Product information: Remodulin (treprostinil sodium) injection. Research Triangle Park, NC: United Therapeutics, 2006. Available at: http://www.fda.gov/ cder/foi/label/2006/021272s005lbl.pdf. Accessed February 17, 2008.
9. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004; 44:209-214.
10. Yap RL, Mermel LA. Micrococcus infections in patients receiving epoprostenol by continuous infusion. Eur J Clin Microbiol Infect Dis 2003; 22:704-705.
11. Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcus-associated central venous catheter infections in patients with pulmonary arterial hypertension. Chest 2004; 126:90-94.
12. RubenfireM, Mclaughlin VV, Allen RP, et al. Transition from intravenous epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 2007; 132:757-763.
13. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006; 81:1159-1171.
14. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med 2005; 258:199-215.
15. Prescribing information: Flolan (epoprostenol sodium) for injection. Research Triangle Park, NC: GlaxoSmithKline, 2008. Available at: http://us.gsk.com/products/assets/us_flolan.pdf. Accessed June 15, 2007.
16. Brannan DK. Biology of microbes. In: Brannan DK, ed. Cosmetic microbiology: a practical handbook. Washington, DC: CRC Press, 1997:48-49.
17. Aronhoff DM, Peres CM, Serezani CH, et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol 2007; 178:1628-1634.
18. Lindemann S, Gierer C, Darius H. Prostacyclin inhibits adhesion of polymorphonuclear leukocytes to human vascular endothelial cells due to adhesion molecule independent regulatory mechanisms. Basic Res Cardiol 2003; 98:8-15.
19. Eisenhut T, Sinha B, Grottrup-Wolfers E, et al. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-α in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 1993; 26:259-264.
20. Czeslick EG, Simm A, Grond S, Silber RE, Sablotzki A. Inhibition of intracellular tumor necrosis factor (TNF)-α and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest 2003; 33:1013-1017.
21. Dumble LJ, Gibbons S, Tejpal N, et al. 15 AU81, a prostacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporine. Transplantation 1993; 55:1124-1128.
22. Centers for Disease Control and Prevention. Bloodstream infections among patients treated with intravenous epoprostenol and intravenous treprostinil for pulmonary arterial hypertension - seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2007; 56:170-172.
23. Baciu A, Stratton K, Burke SP, eds. The future of drug safety: promoting and protecting the health of the public. Washington, DC: Institute of Medicine, 2006.